Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Adial Pharmaceuticals (ADIL) Income from Continuing Operations (2022 - 2024)

Adial Pharmaceuticals' Income from Continuing Operations history spans 3 years, with the latest figure at 2070790.0 for Q4 2024.

  • For Q4 2024, Income from Continuing Operations fell 8.74% year-over-year to 2070790.0; the TTM value through Dec 2024 reached 13197451.0, down 88.48%, while the annual FY2025 figure was 7649895.0, 42.04% up from the prior year.
  • Income from Continuing Operations for Q4 2024 was 2070790.0 at Adial Pharmaceuticals, up from 2191803.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1347700.0 in Q3 2023 and bottomed at 6476560.0 in Q1 2024.
  • The 3-year median for Income from Continuing Operations is 2349090.5 (2023), against an average of 2717811.33.
  • The largest annual shift saw Income from Continuing Operations soared 60.76% in 2023 before it plummeted 189.15% in 2024.
  • A 3-year view of Income from Continuing Operations shows it stood at 2549674.0 in 2022, then increased by 25.31% to 1904437.0 in 2023, then fell by 8.74% to 2070790.0 in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Income from Continuing Operations are 2070790.0 (Q4 2024), 2191803.0 (Q3 2024), and 2458298.0 (Q2 2024).